News
Is It Worth Investing in Workday (WDAY) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts
Why This 1 Computer and Technology Stock Could Be a Great Addition to Your Portfolio
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium
Home Depot (HD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Home Depot (HD) reported $45.28 billion in revenue for the quarter ended July 2025, representing a year-over-year increase of 4.9%. EPS of $4.68 for the same period compares to $4.67 a year ago.
The
Salesforce.com (CRM) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Is It Worth Investing in AutoZone (AZO) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Compared to Estimates, Amer Sports, Inc. (AS) Q2 Earnings: A Look at Key Metrics
For the quarter ended June 2025, Amer Sports, Inc. (AS) reported revenue of $1.24 billion, up 24.4% over the same period last year. EPS came in at $0.06, compared to $0.05 in the year-ago quarter.
Compared to Estimates, Opera Limited (OPRA) Q2 Earnings: A Look at Key Metrics
Opera Limited Sponsored ADR (OPRA) reported $142.96 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 30.3%. EPS of $0.26 for the same period compares to
Why Axon Enterprise (AXON) is a Top Stock for the Long-Term
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
One of our most popular
Shoals Technologies Group (SHLS) Crossed Above the 50-Day Moving Average: What That Means for Investors
Shoals Technologies Group (SHLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SHLS broke through the 50-day moving average
Transocean Stock Plunges 43% in a Year: Time to Hold or Sell?
In the past year, Transocean Ltd.’s RIG shares have lost 43.4%, underperforming the Oil & Gas Drilling sub-industry’s decline of 39.4%. This decrease also outpaced the broader oil and energy sector
The Zacks Analyst Blog Highlights Shopify, Microsoft, Roblox and Amazon
For Immediate Release
Chicago, IL – August 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
The Zacks Analyst Blog Highlights Fortis, New Jersey Resources, ONE Gas and Diageo
For Immediate Release
Chicago, IL – August 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
Chevron Resumes Venezuela Oil Exports Amid Shifting U.S. Sanctions
Chevron Corporation CVX has dispatched Venezuela’s two oil shipments to the United States after Washington restored its license to operate in the sanctioned nation. The Mediterranean Voyager and
The Zacks Analyst Blog Highlights Walmart, Abercrombie & Fitch, Urban Outfitters and Burlington Stores
For Immediate Release
Chicago, IL – August 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
What Analyst Projections for Key Metrics Reveal About Canadian Solar (CSIQ) Q2 Earnings
In its upcoming report, Canadian Solar (CSIQ) is predicted by Wall Street analysts to post quarterly earnings of $0.76 per share, reflecting an increase of 3700% compared to the same period last
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?
A strong stock as of late has been Brainsway Ltd. Sponsored ADR (BWAY). Shares have been marching higher, with the stock up 22.8% over the past month. The stock hit a new 52-week high of $14.86 in
4 Stocks With Robust Sales Growth Worth Adding to Your Portfolio
Markets started 2025 on a strong footing but have since faced considerable volatility. Tariff-related pressures and geopolitical uncertainty persist, yet expectations for a September FOMC rate cut
Tesla's 10X P/S Premium: Is the Stock a Buy, Hold or Sell Now?
Tesla TSLA is one of those stocks whose valuation has long been divorced from its fundamentals. It has always traded at a premium, backed by promises of its long-term potential. For years, that
3 Top Dividend Stocks to Maximize Your Retirement Income
Strange but true: seniors fear death less than running out of money in retirement.
And older Americans have legitimate reasons for this worry, even if they have dutifully saved for their golden
Ferrari's Purosangue SUV Emerges as a Core Growth Driver in Q2
Ferrari N.V.’s RACE Purosangue has quickly proven itself as more than a headline-grabbing experiment. In the second quarter of 2025, the SUV was highlighted alongside the 296 GTS and Roma Spider as
The Zacks Analyst Blog Highlights Watts Water, Armstrong World and Levi Strauss
For Immediate Release
Chicago, IL – August 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
U.S. Natural Gas Futures Extend Weekly Losses on High Supply
The U.S. Energy Department's latest inventory report showed a higher-than-expected increase in natural gas supplies. The bearish inventory numbers, together with strong production levels, put
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus


